ArticleFrontiers in oncology2026
Lymphoepithelioma-like carcinoma of the bladder: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoepithelioma-like carcinoma (LELCB), Lymphoepithelioma-like carcinoma of the bladder (LELCB) is a rare subtype of urothelial carcinoma, accounting for less than 1.3% of all pathological types of malignant bladder tumors. Due to the rarity of the cases, surgical resection and postoperative adjuvant therapy are currently the main treatment methods, and standardized treatment protocols and prognostic factors are not yet fully clarified. This article reported a case of an 86-year-old woman who visited the hospital due to painless gross hematuria. Urinary system color Doppler ultrasound and computed tomography (CT) of the bladder both suggested a tumor on the right anterior wall of the bladder. After transurethral resection of bladder tumor, the postoperative pathology confirmed LELCB. The patient relapsed after 11 months of regular chemotherapy. Due to aging and the occurrence of complications such as hypertension, diabetes, and COPD, the patient still chose to undergo partial cystectomy after recurrence. Postoperative pathology still indicated lymphoepithelioma-like carcinoma of the bladder. Unfortunately, the patient did not undergo further adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.